190 related articles for article (PubMed ID: 22157599)
1. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo.
Tada H; Kawashiri MA; Ikewaki K; Terao Y; Noguchi T; Nakanishi C; Tsuchida M; Takata M; Miwa K; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
Circ Cardiovasc Genet; 2012 Feb; 5(1):35-41. PubMed ID: 22157599
[TBL] [Abstract][Full Text] [Related]
2. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
3. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
[TBL] [Abstract][Full Text] [Related]
4. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production.
Millar JS; Maugeais C; Ikewaki K; Kolansky DM; Barrett PH; Budreck EC; Boston RC; Tada N; Mochizuki S; Defesche JC; Wilson JM; Rader DJ
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):560-5. PubMed ID: 15637307
[TBL] [Abstract][Full Text] [Related]
5. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
Ouguerram K; Magot T; Zaïr Y; Marchini JS; Charbonnel B; Laouenan H; Krempf M
J Pharmacol Exp Ther; 2003 Jul; 306(1):332-7. PubMed ID: 12684543
[TBL] [Abstract][Full Text] [Related]
6. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Millar JS; Brousseau ME; Diffenderfer MR; Barrett PH; Welty FK; Faruqi A; Wolfe ML; Nartsupha C; Digenio AG; Mancuso JP; Dolnikowski GG; Schaefer EJ; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
[TBL] [Abstract][Full Text] [Related]
7. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B
Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
[TBL] [Abstract][Full Text] [Related]
9. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
[TBL] [Abstract][Full Text] [Related]
10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of cholesterol ester of apolipoprotein B100-containing lipoproteins in dogs: evidence for disregarding cholesterol ester transfer.
Bailhache E; Briand F; Nguyen P; Krempf M; Magot T; Ouguerram K
Eur J Clin Invest; 2004 Aug; 34(8):527-34. PubMed ID: 15305886
[TBL] [Abstract][Full Text] [Related]
12. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
13. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
14. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
Chan DC; Watts GF; Wang J; Hegele RA; van Bockxmeer FM; Barrett PH
Clin Endocrinol (Oxf); 2008 Jul; 69(1):45-51. PubMed ID: 18031309
[TBL] [Abstract][Full Text] [Related]
15. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
17. Autosomal recessive hypercholesterolemia: a mild phenotype of familial hypercholesterolemia: insight from the kinetic study using stable isotope and animal studies.
Tada H; Kawashiri MA; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
J Atheroscler Thromb; 2015; 22(1):1-9. PubMed ID: 25399932
[TBL] [Abstract][Full Text] [Related]
18. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Wolffenbuttel BH; Franken AA; Vincent HH;
J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
Farsang C; Athyros V; Gaw A;
Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
